6 Athira Pharma LIFT-AD topline results (press release)September 3, 2024 announcement that fosgonimeton (a distinct HGF/c-Met modulator) did not meet the primary or key secondary endpoints in the Phase 2/3 LIFT-AD Alzheimers trial
PPE & Containment Apply appropriate gloves, eye protection, protective clothing, ventilation, and containment
The safety was preliminarily verified: The acute toxicity test showed that a single subcutaneous injection of AOD 9604 (50 mg/kg) did not cause death or obvious toxic reactions in mice
Because of this, it is often included in research focused on wound healing, recovery support, and tissue regeneration
Preclinical colitis models: KPV reduces mucosal inflammation in preclinical colitis models, with demonstrated reductions in TNF-, IL-6, and other pro-inflammatory markers
Mutation at Cys2991 abolishes redox sensitivity while maintaining activation by DNA damage